Cipher Pharmaceuticals CPHRF Stock
Cipher Pharmaceuticals Price Chart
Cipher Pharmaceuticals CPHRF Financial and Trading Overview
Cipher Pharmaceuticals stock price | 6.78 USD |
Previous Close | 2.79 USD |
Open | 2.85 USD |
Bid | 0 USD x 0 |
Ask | 0 USD x 0 |
Day's Range | 2.79 - 2.79 USD |
52 Week Range | 1.25 - 5.38 USD |
Volume | 401 USD |
Avg. Volume | 3.87K USD |
Market Cap | 72.68M USD |
Beta (5Y Monthly) | 0.980759 |
PE Ratio (TTM) | 2.6588573 |
EPS (TTM) | 0.8 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.59 USD |
CPHRF Valuation Measures
Enterprise Value | 37.71M USD |
Trailing P/E | 2.6588573 |
Forward P/E | 5.5836 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 3.607776 |
Price/Book (mrq) | 1.0535094 |
Enterprise Value/Revenue | 1.872 |
Enterprise Value/EBITDA | 3.255 |
Trading Information
Cipher Pharmaceuticals Stock Price History
Beta (5Y Monthly) | 0.980759 |
52-Week Change | 52.45% |
S&P500 52-Week Change | 20.43% |
52 Week High | 5.38 USD |
52 Week Low | 1.25 USD |
50-Day Moving Average | 2.59 USD |
200-Day Moving Average | 2.57 USD |
CPHRF Share Statistics
Avg. Volume (3 month) | 3.87K USD |
Avg. Daily Volume (10-Days) | 880 USD |
Shares Outstanding | 25.34M |
Float | 23.83M |
Short Ratio | 0.97 |
% Held by Insiders | 42.65% |
% Held by Institutions | 0.20% |
Shares Short | 11.43K |
Short % of Float | N/A |
Short % of Shares Outstanding | 0.040% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 134.58% |
Operating Margin (ttm) | 52.10% |
Gross Margin | 80.91% |
EBITDA Margin | 57.51% |
Management Effectiveness
Return on Assets (ttm) | 10.02% |
Return on Equity (ttm) | 50.44% |
Income Statement
Revenue (ttm) | 20.15M USD |
Revenue Per Share (ttm) | 0.8 USD |
Quarterly Revenue Growth (yoy) | -9.80% |
Gross Profit (ttm) | 16.68M USD |
EBITDA | 11.59M USD |
Net Income Avi to Common (ttm) | 27.11M USD |
Diluted EPS (ttm) | 1.05 |
Quarterly Earnings Growth (yoy) | 22.19% |
Balance Sheet
Total Cash (mrq) | 33.43M USD |
Total Cash Per Share (mrq) | 1.32 USD |
Total Debt (mrq) | 403K USD |
Total Debt/Equity (mrq) | 0.6 USD |
Current Ratio (mrq) | 4.374 |
Book Value Per Share (mrq) | 2.65 |
Cash Flow Statement
Operating Cash Flow (ttm) | 13.29M USD |
Levered Free Cash Flow (ttm) | 6.54M USD |
Profile of Cipher Pharmaceuticals
Country | United States |
State | ON |
City | Mississauga |
Address | 5750 Explorer Drive |
ZIP | L4W 0A9 |
Phone | 905-602-5840 |
Website | https://www.cipherpharma.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne; Lipofe indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.
Q&A For Cipher Pharmaceuticals Stock
What is a current CPHRF stock price?
Cipher Pharmaceuticals CPHRF stock price today per share is 6.78 USD.
How to purchase Cipher Pharmaceuticals stock?
You can buy CPHRF shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cipher Pharmaceuticals?
The stock symbol or ticker of Cipher Pharmaceuticals is CPHRF.
Which industry does the Cipher Pharmaceuticals company belong to?
The Cipher Pharmaceuticals industry is Drug Manufacturers-Specialty & Generic.
How many shares does Cipher Pharmaceuticals have in circulation?
The max supply of Cipher Pharmaceuticals shares is 24.05M.
What is Cipher Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Cipher Pharmaceuticals PE Ratio is 8.47500000 now.
What was Cipher Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Cipher Pharmaceuticals EPS is 0.8 USD over the trailing 12 months.
Which sector does the Cipher Pharmaceuticals company belong to?
The Cipher Pharmaceuticals sector is Healthcare.